Physician profile
Lin Liu
NPI 1063809473
$4,127.95
in general payments reported to CMS, 2019-2025
34 companies · $669 in 2025
The $669 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $137 · 2021: $372 · 2022: $731 · 2023: $857 · 2024: $781 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $623.48 | 2019-2025 | |
| Gilead Sciences, INC. | $493.76 | 2020-2025 | Livdelzi, Vemlidy |
| Lilly USA, LLC | $467.14 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $339.66 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $237.36 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.59 | 2021-2025 | Jardiance |
| Amgen INC. | $185.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $169.54 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Aurinia Pharma U.S., INC. | $150.49 | 2023 | Lupkynis |
| Merck Sharp & Dohme LLC | $142.58 | 2019-2023 | Belsomra |
| Allergan, INC. | $117.28 | 2019 | |
| Abbott Laboratories | $112.06 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $110.31 | 2023-2025 | Voquezna |
| Amarin Pharma, INC. | $84.43 | 2019-2022 | |
| Exact Sciences Corporation | $76.77 | 2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.27 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.45 | 2020-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $58.56 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $49.57 | 2021-2022 | |
| Eisai INC. | $46.92 | 2024-2025 | |
| Redhill Biopharma INC. | $38.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.92 | 2022 | |
| Genentech USA, INC. | $34.61 | 2019-2020 | |
| Medtronic, INC. | $24.02 | 2022 | |
| Meridian Bioscience INC. | $23.60 | 2024 | |
| Aimmune Therapeutics, INC. | $22.72 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.73 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.38 | 2022 | |
| Evoke Pharma, INC. | $18.21 | 2022 | |
| Pfizer INC. | $17.54 | 2024 | |
| Seqirus USA INC | $16.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2021 | |
| Vivus LLC | $12.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.